Spegra Tablet (PEP) for HIV Treatment

Description

 

Generic Name:

Spegra Tablet (PEP) is an antiretroviral HIV medicine used for Post-Exposure Prophylaxis (PEP) to reduce the risk of HIV infection after potential exposure.

 

It contains a combination of Dolutegravir, Tenofovir Disoproxil Fumarate, and Lamivudine, which work together to block HIV replication and prevent the virus from establishing infection in the body.

 

Composition:

Each Spegra Tablet (PEP) contains three antiretroviral medicines:

 

• Dolutegravir – an integrase strand transfer inhibitor that blocks HIV from replicating in human cells.
• Tenofovir Disoproxil Fumarate – a nucleotide reverse transcriptase inhibitor (NRTI) that prevents viral DNA synthesis.
• Lamivudine – an NRTI that further inhibits HIV replication and reduces viral load.

These medicines work together as combination antiretroviral therapy (ART).

 

Indication:

Spegra Tablet (PEP) is indicated for HIV Post-Exposure Prophylaxis (PEP) to reduce the risk of HIV-1 infection after potential exposure such as:

• unprotected sexual contact

• needlestick injuries

• exposure to infected blood or bodily fluids

PEP treatment should be started within 72 hours of exposure.

 

Storage Instructions:

• Store at room temperature (15-25°C).
• Keep away from direct sunlight and moisture.
• Keep out of reach of children and pets.
• Do not use expired tablets.

Spegra Tablet Medicine Uses:

• PEP treatment: Helps prevent HIV infection if started within 72 hours of exposure.
• Reduces viral replication: Lowers the risk of the virus establishing an infection.
• Supports immune defense: Helps maintain immune function after potential HIV exposure.

Spegra Tablet Price:

Spegra Tablet (PEP) is currently available online at a discounted price of ₹3,100, reduced from the original price of ₹4,389. Prices may vary depending on availability and pharmacy location.

 

Benefits of Spegra Tablet (PEP):

• Highly effective HIV prevention when started within 72 hours of exposure

• Combination antiretroviral therapy improves protection

• Convenient once-daily dosing

• Proven effectiveness when the full 28-day course is completed

• Helps reduce the risk of HIV infection after high-risk exposure

Spegra Tablet Side Effects:

Common side effects include:

• Nausea
• Headache
• Fatigue
• Diarrhea
• Insomnia

Spegra Tablet Serious Side Effects Include:

• Severe allergic reactions (rash, swelling, difficulty breathing)
• Liver problems (yellowing of skin/eyes, dark urine)
• Lactic acidosis (weakness, irregular heartbeat, muscle pain)
• Kidney dysfunction (decreased urination, swelling in legs/ankles)

How to Use the Spegra Medicine:

• Take one tablet daily with or without food.
• Swallow the tablet whole with a glass of water.
• Complete the full 28-day treatment course.
• Do not stop the medication without consulting a doctor.

How the Spegra Medicine Works:

Spegra PEP Tablet contains three antiretroviral drugs that work together to block HIV replication, preventing the virus from integrating into human cells and establishing an infection.

 

What If You Forget to Take the Medicine?

• Take the missed dose as soon as you remember.
• If it is close to your next dose, skip the missed dose and continue as scheduled.
• Do not take a double dose to make up for the missed one.

Quick Tips:

• Start PEP within 72 hours of exposure for maximum effectiveness.
• Complete the 28-day course to ensure full protection.
• Use condoms and safe practices to prevent further exposure.
• Stay in touch with your doctor for regular follow-ups.

 

Safety Advice

Caution is advised when consuming alcohol with Spegra Tablet. Please consult your doctor for guidance.

 

Spegra Tablet is unsafe to use during pregnancy due to potential harm to the developing baby. It may only be prescribed in life-threatening situations where benefits outweigh the risks. Please consult your doctor.

 

There is insufficient information on the use of Spegra Tablet while breastfeeding. Please consult your doctor before use.

 

It is uncertain whether Spegra Tablet affects your ability to drive. Avoid driving if you experience drowsiness, dizziness, or reduced alertness.

 

Limited data is available on the safety of Spegra Tablet in patients with kidney disease. Dose adjustments may be necessary. Please consult your doctor.

 

Spegra Tablet should be used with caution in patients with liver disease. Dose adjustments may be required based on the severity of the condition. Please consult your doctor.

Manufacturer:

Spegra Tablet is manufactured by Emcure Pharmaceuticals, a leading pharmaceutical company specializing in antiretroviral HIV medicines.

 

FAQs:

Q: What is Spegra Tablet used for?
A: Spegra Tablet is an antiretroviral HIV medicine used for post-exposure prophylaxis (PEP) to reduce the risk of HIV infection after potential exposure.

 

Q: How soon should I take Spegra PEP after exposure?
A: Ideally, within 72 hours of potential HIV exposure, the sooner, the better.

 

Q: Can I stop taking PEP if I feel fine?
A: No, you must complete the full 28-day course for maximum protection.

 

Q: Does Spegra PEP guarantee 100% protection against HIV?
A: While highly effective, PEP is not 100% foolproof. Safe sex and prevention methods should still be followed.

 

Related Lab Tests:

• HIV Testing (Baseline, 4 Weeks, 12 Weeks Post-Exposure)
• Liver and Kidney Function Tests
• Complete Blood Count (CBC)
• Hepatitis B and C Screening

Other Resources 

HIV.gov – Dolutegravir (DTG): Patient Drug Info

Additional information

Manufacturer	Emcure